Research We’ve Supported

Glaucoma Research we’ve supported

Glaucoma NZ has been funding research projects and investigations into glaucoma since 2005. We provide a high quality independent assessment of research projects before funding to assure the very best use of the limited funds available for research.

Our researchers investigate the causes of glaucoma and how it can be better treated. We collaborate both locally and internationally across research areas that include gene therapy, mitochondrial research, clinical genetics and more. If you have an interest in helping Glaucoma NZ support research into glaucoma, please consider a donation.

Enjoy reading the articles about the latest research we and others have supported.

Read about the research

2022  Using machine learning to develop a risk score for glaucoma

A ground-breaking study that’s currently underway in New Zealand is a potential gamechanger for the early detection of glaucoma. Dr William Schierding and Professor Helen Danesh-Meyer are conducting the research that better predicts the likelihood of developing glaucoma based on environmental and biological profiles.


2020 – Modelling the use of OCT to prevent rare cases of vision loss

This is one of the first population-based studies of glaucoma prevalence using modern OCT scans to determine a diagnosis of early glaucoma (when visual fields are normal) and has implications for public health planning in New Zealand.


2019 – Identifying important demographic parameters for at risk populations susceptible to developing an acute angle closure

Research focused on identifying important demographic parameters that might identify which groups are more susceptible to developing an acute angle closure crisis


2018  – ‘Artificial Intelligence and Defining Glaucoma’

In line with worldwide studies, De Souza’s research focused on training a deep learning algorithm to detect glaucoma


2017 – Nailfold Capillary Abnormalities in Primary Open Angle Glaucoma

This study aims to identify which nailfold capillary abnormalities occur in glaucoma and to establish whether nailfold capillaroscopy can be used to predict glaucoma severity and the risk of central vision loss.


2012 – Recruitment and management of glaucoma patients to assess their current disease state, monitoring and treatment, and how the detection of new patients may be improved

by University of Otago, Josh Erceg.


2011  – Connexin 43 changes in Open-Angle glaucoma and the role of astrocytes in glaucoma

University of Otago, Peny Lin.


2008 – What do people with glaucoma know about their condition?

A comparative cross-sectional incidence and prevalence survey by Dr Helen V Danesh-Meyer MD, FRANZCO, & Narme C Deva MBChB.


2007 – ‘Determination of the genetic basis for glaucoma in a New Zealand population’

by Dr Andrea Vincent


Dr Jesse Gale discusses future directions in glaucoma research and treatment

The direction that Glaucoma Research is taking in the future and exciting possibilities are discussed at the virtual GNZ Glaucoma Patient Symposium 2020

Glaucoma Research

Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye

Assessing tear film parameters, ocular surface characteristics, and dry eye symptomology in patients receiving topical anti-glaucoma medications.


Depression and quality of life with glaucoma

Determining the prevalence of depression and its association with visual field impairment, quality of life, objective assessment of visual function, and glaucoma severity in elderly patients with glaucoma.


Glaucoma and the brain: Trans-synaptic degeneration, structural change, and implications for neuroprotection

A  hypothesis suggesting that glaucoma is a neurodegenerative disease. The basis for this has been the finding of central nervous system changes in glaucoma patients on histology and neuroimaging.


High rate of incidental glaucoma detection in New Zealand

Investigating how glaucoma is initially detected in New Zealanders and what factors aroused disease suspicion.


Neuroinflammation as a target for glaucoma therapy

The pathogenesis of glaucoma is still not fully clarified but a growing body of evidence suggests that neuroinflammation and immune response are part of the sequence of pathological events leading to optic neuropathy.


Ocular Surface disease and quality of life in patients with glaucoma

Investigating the relationship between ocular surface disease and glaucoma-related quality of Life (QoL), glaucoma severity, and treatment in patients with open-angle glaucoma.


Is primary open-angle glaucoma an ocular manifestation of systemic disease?

Abnormalities in blood flow to the back of the eye and the role it plays in glaucoma.


Neuroprotection in glaucoma: recent and future directions

The concept of neuroprotective therapy for glaucoma is that damage to retinal ganglion cells (RGCs) may be prevented by intervening in neuronal death pathways. This review focuses on strategies for neuroprotection and summarizes preclinical studies that have investigated potential agents over the last 2 years.


Want to Volunteer for a Clinical Research Study?

You can find out more and register your interest in taking part in current or future research with Glaucoma NZ.



Every donation, no matter how large or small, will help support research into new ways to diagnose, treat and prevent blindness from glaucoma.

Donate Now


Help us make a difference

Your donation will help us to save sight and continue helping people with glaucoma get access to the information and support they need.


Join Glaucoma NZ

Get the support you need

Glaucoma NZ provides free information, support materials and invites to events to help you and others live well with glaucoma.

Join Glaucoma NZ